Dance Biopharm Finds Its Rhythm

Dance Biopharm had a lot to celebrate in 2018 and if all goes according to plan the private biotech company will have even more to celebrate this year. The company's flagship product – an insulin product delivered via a smart handheld soft mist inhaler – is currently in two confirmatory phase II studies in type 1 and 2 diabetes patients, and Dance plans to initiate two phase III programs in type 2 diabetes patients in 2019. "2018 was a year where Dance really started to build momentum and come out of stealth mode to move toward a commercially focused company," said Anne Whitaker, who joined Dance in September as director and CEO. Whitaker has worked with diabetes pharmaceutical products at all stages of the product lifecycle and is expected to lead the company's transformation from late-stage development to preparing its lead clinical asset, Dance 501, for commercialization.  In June 2018, the company completed a new private equity financing round securing $24.5 million. SternAegis Ventures, through Aegis Capital Corp., acted as the exclusive placement agent for the offering.  Molex Ventures, a subsidiary of Koch Industries also made a substantial equity investment in Dance and helped anchor the round. "This company is well positioned to transform diabetes care by taking the complexity out of insulin delivery and addressing the specific needs of ...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news